Cision PR Newswire, Author at World Lifestyler

No Result

View All Result

WORLD LIFESTYLER

No Result

View All Result

Home Author

Cision PR Newswire

Press Releases - Lifestyle

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

June 5, 2026

Press Releases - Lifestyle

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

June 5, 2026

Press Releases - Lifestyle

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

June 5, 2026

Press Releases - Lifestyle

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

June 5, 2026

Press Releases

Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

June 5, 2026

Press Releases - Food & Drink

Corner Bakery Offers $50 Off Catering for Game-Day Watch Parties

June 5, 2026

Press Releases - Lifestyle

BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit

June 5, 2026

Press Releases - Lifestyle

Europe’s competitiveness hinges on integrated industrial electrification, new Eurelectric report shows

June 5, 2026

Press Releases - Lifestyle

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

June 5, 2026

Press Releases

Corgi Launches Suite of Six Fixed Income ETFs on Cboe BZX, Capping a Week of 50 Fund Launches

June 5, 2026

Page 987 of 3892 Prev 1 … 986 987 988 … 3,892 Next

No Result

View All Result

Home

Cision PR Newswire

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Corner Bakery Offers $50 Off Catering for Game-Day Watch Parties

BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit

Europe’s competitiveness hinges on integrated industrial electrification, new Eurelectric report shows

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Corgi Launches Suite of Six Fixed Income ETFs on Cboe BZX, Capping a Week of 50 Fund Launches

Recommended

Maya HTT Launches the TMG™ SDK, a High-Performance Thermal Simulation Solution

AAR to host 2026 Investor Day

Popular News

The Philippines strengthens its food safety system. Industry representatives visit Poland to explore European solutions

Kuehn Law Encourages Investors of Flowco Holdings Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Sable Offshore Corp to Contact Law Firm

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

Connect with us

About & Contact

Explore Content

Legal & Privacy

Tiny Media Brands